Login / Signup
Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.
Weixian Hu
Published in:
Thoracic cancer (2019)
Keyphrases
</>
high throughput
risk factors
real time pcr